MESO-Rx
Anabolic Steroids
Can touching a barbell in the gym get you sick with the coronavirus?
- Thread starter Michael Scally MD
- Start date
Michael Rapino from Live Nation:
Asked for his longview on business in general, Rapino said, “In a survey we just posted, we talked to 10,000 casual and ongoing ticketbuyers and the data is pretty compelling: 90% of fans are saying ‘I can’t wait to get back to the show,’ and I think our refund rate says everything — we’re running somewhere between a 5-10 refund rate right now on a global basis, that’s much lower in Europe [which is farther ahead in the recovery process], and that’s not out of line for when we reschedule a traditional tour [under normal circumstances]. Now we’re just going to [watch] the science and see when we can back out there on a safe manner.
Asked how long the company can continue to operate with an extended shutdown, Rapino directed the question to president Joe Berchtold. “We have $870 million in available cash, $900 million untapped, so that’s $1.7 billion in untapped liquidity to start with. So we can go through this year without doing any shows at scale without any concern, even though we’re not likely to have a huge volume of shows,” he said. “And in the fourth quarter we’ll have ticket sales in some large scale for next year — we’re already seeing the NFL schedule announced today and most teams are going on sale with their tickets, so that will help drive some of our ticketing and sponsorship businesses. Getting through this year without any additional liquidity is not a concern.”
Asked for his longview on business in general, Rapino said, “In a survey we just posted, we talked to 10,000 casual and ongoing ticketbuyers and the data is pretty compelling: 90% of fans are saying ‘I can’t wait to get back to the show,’ and I think our refund rate says everything — we’re running somewhere between a 5-10 refund rate right now on a global basis, that’s much lower in Europe [which is farther ahead in the recovery process], and that’s not out of line for when we reschedule a traditional tour [under normal circumstances]. Now we’re just going to [watch] the science and see when we can back out there on a safe manner.
Asked how long the company can continue to operate with an extended shutdown, Rapino directed the question to president Joe Berchtold. “We have $870 million in available cash, $900 million untapped, so that’s $1.7 billion in untapped liquidity to start with. So we can go through this year without doing any shows at scale without any concern, even though we’re not likely to have a huge volume of shows,” he said. “And in the fourth quarter we’ll have ticket sales in some large scale for next year — we’re already seeing the NFL schedule announced today and most teams are going on sale with their tickets, so that will help drive some of our ticketing and sponsorship businesses. Getting through this year without any additional liquidity is not a concern.”
[OA] Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
BACKGROUND - Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use.
METHODS - We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department (study baseline).
The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score.
RESULTS - Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376 patients, during a median follow-up of 22.5 days, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days); 45.8% of the patients were treated within 24 hours after presentation to the emergency department, and 85.9% within 48 hours.
Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs. 360). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In the main analysis, there was no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32). Results were similar in multiple sensitivity analyses.
CONCLUSIONS - In this observational study involving patients with Covid-19 who had been admitted to the hospital, HYDROXYCHLOROQUINE ADMINISTRATION WAS NOT ASSOCIATED WITH EITHER A GREATLY LOWERED OR AN INCREASED RISK OF THE COMPOSITE END POINT OF INTUBATION OR DEATH. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed.
Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine 2020. https://doi.org/10.1056/NEJMoa2012410
BACKGROUND - Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use.
METHODS - We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department (study baseline).
The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score.
RESULTS - Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376 patients, during a median follow-up of 22.5 days, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days); 45.8% of the patients were treated within 24 hours after presentation to the emergency department, and 85.9% within 48 hours.
Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs. 360). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In the main analysis, there was no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32). Results were similar in multiple sensitivity analyses.
CONCLUSIONS - In this observational study involving patients with Covid-19 who had been admitted to the hospital, HYDROXYCHLOROQUINE ADMINISTRATION WAS NOT ASSOCIATED WITH EITHER A GREATLY LOWERED OR AN INCREASED RISK OF THE COMPOSITE END POINT OF INTUBATION OR DEATH. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed.
Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine 2020. https://doi.org/10.1056/NEJMoa2012410
When Judy Mikovits co-authored a 2009 research paper that linked the mysterious condition known as chronic fatigue syndrome to a retrovirus that came from mice, thousands of sick patients hoping for relief rallied behind her. The scientific riddle was solved, they thought.
Less than two years later those hopes were dashed when follow-up studies failed to replicate Mikovits’s findings and the prestigious journal “Science” retracted the paper. Researchers posited that the study’s inaccurate conclusions were the result of contamination of the lab samples, and the theory that a virus might be the source of the still-mysterious condition died.
But Mikovits’s conviction that her theory was correct, and her belief that the top scientific minds in the U.S. conspired to ruin her career, never faded.
She has now accused the scientific establishment of conspiracy again. In a film called “Plandemic,” and in a recently published book that topped the Amazon best sellers chart this week, she makes a bizarre and false claim: that the doctors and experts shaping public policy in response to the novel coronavirus pandemic have silenced dissenting voices and misled the public for sinister reasons.
She falsely claims that wealthy people intentionally spread the virus to increase vaccination rates, and that wearing face masks is harmful.
The coronavirus-related theories Mikovits presented defy accepted science and wilt under scrutiny, according to dozens of experts who spoke up after “Plandemic” trended this week.
The film is so questionable that social media platforms including Facebook, YouTube and Vimeo on Thursday scrubbed it from their sites. A Vimeo spokesperson, for example, said that the company “stands firm in keeping our platform safe from content that spreads harmful and misleading health information. The video in question has been removed … for violating these very policies.”
It was the latest chapter in the saga of Mikovits’s troubled career.
Go on social media right now and you are destined to run into someone sharing or promoting a video that has gone viral called PLANDEMIC. They will parrot the points from this video like good little puppets, without taking the time to research who is giving them the information, or the credibility of the information being presented.
This video is pure sensationalism and filled with outrageous lies and mistruths. And the information being shared is being shared by someone who is a known charlatan. If you believe in and promote this video, you’ve simply fallen for the trick.
First, who is Dr. Judy Mikovits? Google her name. What do you find?
I think the first thing a person should notice that sticks out like a giant red flag is her connection to the anti-vaccine movement. This person has become a hero to a movement that claims vaccines are dangerous, cause autism, and kill people, thusly making her the hero of a movement that has caused a resurgence in long conquered diseases like the measles.
The next red flag a person should pay attention to is the word DISCREDITED which always appears next to her name. When a scientist is kicked out of the scientific community and then becomes a champion for conspiracy theories, some might say this is anything but a coincidence. But unlike conspiracy theorists, who connect invisible dots no one else can see, there are dots to be connected here that are as large as planets.
Plandemic follows the straightforward and rudimentary template of a conspiracy theory propaganda film, much like others that have come before it like Zeitgeist or Loose Change (videos claiming 9/11 was an inside job). ...
Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-19)
The rapid spread of COVID-19 in many areas of the world calls for preventive health measures. Although basic guidelines on infection control are suggested, treatment has remained the best choice to avert mortality. However, for the time being, there are no known vaccines for the disease.
In this paper, a multinomial logistic regression was used to predict clinical outcomes of patients infected with COVID-19 based on 25-hydroxyvitamin D [25(OH)D] levels, the barometer for Vitamin D status. A retrospective multicentre study of 212 cases with laboratory-confirmed infection of SARS-CoV-2 was conducted. Data pertaining to clinical features and serum 25(OH)D levels were extracted from the medical records.
For statistical analysis, Mann-Whitney U and χ² tests were used to compare differences in the clinical outcomes. Multinomial logistic regression was used to explore the association between serum 25(OH)D level and clinical outcomes of the cases. Frequency and percentage were used for categorical variables. Mean was used for continuous variables. A p-value below 0.01 was considered statistically significant.
Of the 212 cases of COVID-19, majority had ordinary clinical outcome. Mean serum 25(OH)D level was 23.8 ng/ml. Serum 25(OH)D level was lowest in critical cases, but highest in mild cases. Serum 25(OH)D levels were statistically significant among clinical outcomes. Majority had insufficient Vitamin D status, most of them were not severe. Vitamin D status is significantly associated with clinical outcomes.
A multinomial logistic regression analysis reported that for each standard deviation increase in serum 25(OH)D, the odds of having a mild clinical outcome rather than a severe outcome were approximately 7.94 times (OR=0.126, p<0.001) while interestingly, the odds of having a mild clinical outcome rather than a critical outcome were approximately 19.61 times (OR=0.051, p<0.001). The results suggest that an increase in serum 25(OH)D level in the body could either improve clinical outcomes or mitigate worst (severe to critical) outcomes, while a decrease in serum 25(OH)D level in the body could worsen clinical outcomes of COVID-2019 patients.
In conclusion, this study provides substantial information to clinicians and health policy-makers. Vitamin D supplementation could possibly improve clinical outcomes of patients infected with COVID-19. Further research should conduct randomized controlled trials and large population studies to evaluate this recommendation.
Alipio, Mark, Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-19) (April 9, 2020). Available at SSRN: https://ssrn.com/abstract=3571484. or http://dx.doi.org/10.2139/ssrn.3571484.
The rapid spread of COVID-19 in many areas of the world calls for preventive health measures. Although basic guidelines on infection control are suggested, treatment has remained the best choice to avert mortality. However, for the time being, there are no known vaccines for the disease.
In this paper, a multinomial logistic regression was used to predict clinical outcomes of patients infected with COVID-19 based on 25-hydroxyvitamin D [25(OH)D] levels, the barometer for Vitamin D status. A retrospective multicentre study of 212 cases with laboratory-confirmed infection of SARS-CoV-2 was conducted. Data pertaining to clinical features and serum 25(OH)D levels were extracted from the medical records.
For statistical analysis, Mann-Whitney U and χ² tests were used to compare differences in the clinical outcomes. Multinomial logistic regression was used to explore the association between serum 25(OH)D level and clinical outcomes of the cases. Frequency and percentage were used for categorical variables. Mean was used for continuous variables. A p-value below 0.01 was considered statistically significant.
Of the 212 cases of COVID-19, majority had ordinary clinical outcome. Mean serum 25(OH)D level was 23.8 ng/ml. Serum 25(OH)D level was lowest in critical cases, but highest in mild cases. Serum 25(OH)D levels were statistically significant among clinical outcomes. Majority had insufficient Vitamin D status, most of them were not severe. Vitamin D status is significantly associated with clinical outcomes.
A multinomial logistic regression analysis reported that for each standard deviation increase in serum 25(OH)D, the odds of having a mild clinical outcome rather than a severe outcome were approximately 7.94 times (OR=0.126, p<0.001) while interestingly, the odds of having a mild clinical outcome rather than a critical outcome were approximately 19.61 times (OR=0.051, p<0.001). The results suggest that an increase in serum 25(OH)D level in the body could either improve clinical outcomes or mitigate worst (severe to critical) outcomes, while a decrease in serum 25(OH)D level in the body could worsen clinical outcomes of COVID-2019 patients.
In conclusion, this study provides substantial information to clinicians and health policy-makers. Vitamin D supplementation could possibly improve clinical outcomes of patients infected with COVID-19. Further research should conduct randomized controlled trials and large population studies to evaluate this recommendation.
Alipio, Mark, Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-19) (April 9, 2020). Available at SSRN: https://ssrn.com/abstract=3571484. or http://dx.doi.org/10.2139/ssrn.3571484.
Androgen-Deprivation Therapies for Prostate Cancer and Risk Of Infection by SARS-CoV-2
HIGHLIGHTS
· SARS-CoV-2 infected men have a worse clinical outcome than women
· Cancer patients have an increased risk of SARS-CoV-2 infection
· Prostate cancer patients receiving androgen-deprivation therapies appear to be partially protected from the infection
Background Cell entry of SARS-CoV-2 depends on binding of the viral spike (S) proteins to ACE2 and on S protein priming by TMPRSS2. Inhibition of TMPRSS2 may work to block or decrease the severity of SARS-CoV-2 infections. Intriguingly, TMPRSS2 is an androgen-regulated gene that is upregulated in prostate cancer where it supports tumor progression and is involved in a frequent genetic translocation with the ERG gene.
First- or second-generation androgen-deprivation therapies (ADTs) decrease the levels of TMPRSS2. Here we put forward the hypothesis that ADTs may protect patients affected by prostate cancer from SARS-CoV-2 infections.
Materials and methods We extracted data regarding 9280 patients (4532 males) with laboratory-confirmed SARS-CoV-2 infection from 68 hospitals in Veneto, one of the Italian regions that was most affected by the COVID-19 pandemic. The parameters used for each COVID-19 positive patient were gender, hospitalization, admission to intensive care unit (ICU), death, tumor diagnosis, prostate cancer diagnosis, and androgen-deprivation therapy (ADT).
Results There were 9280 SARS-CoV-2 positive patients in the Veneto on April 1, 2020. Overall, males developed more severe complications, were more frequently hospitalized, and had a worse clinical outcome than females. Considering only the Veneto male population (2.4 Million men), 0.2% and 0.3% of non-cancer and cancer patients, respectively, tested positive for SARS-CoV-2.
Comparing the total number of SARS-CoV-2 positive cases, prostate cancer patients receiving ADT had a significantly lower risk of SARS-CoV-2 infection compared to patients who did not receive ADT (OR 4.05; 95% CI 1.55-10.59). A greater difference was found comparing prostate cancer patients receiving ADT to patients with any other type of cancer (OR 5.17; 95% CI 2.02-13.40).
Conclusion Our data suggest that cancer patients have an increased risk of SARS-CoV-2 infections than non-cancer patients. However, prostate cancer patients receiving ADT appear to be partially protected from SARS-CoV-2 infections.
Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532). Annals of Oncology 2020. http://www.sciencedirect.com/science/article/pii/S0923753420397970
HIGHLIGHTS
· SARS-CoV-2 infected men have a worse clinical outcome than women
· Cancer patients have an increased risk of SARS-CoV-2 infection
· Prostate cancer patients receiving androgen-deprivation therapies appear to be partially protected from the infection
Background Cell entry of SARS-CoV-2 depends on binding of the viral spike (S) proteins to ACE2 and on S protein priming by TMPRSS2. Inhibition of TMPRSS2 may work to block or decrease the severity of SARS-CoV-2 infections. Intriguingly, TMPRSS2 is an androgen-regulated gene that is upregulated in prostate cancer where it supports tumor progression and is involved in a frequent genetic translocation with the ERG gene.
First- or second-generation androgen-deprivation therapies (ADTs) decrease the levels of TMPRSS2. Here we put forward the hypothesis that ADTs may protect patients affected by prostate cancer from SARS-CoV-2 infections.
Materials and methods We extracted data regarding 9280 patients (4532 males) with laboratory-confirmed SARS-CoV-2 infection from 68 hospitals in Veneto, one of the Italian regions that was most affected by the COVID-19 pandemic. The parameters used for each COVID-19 positive patient were gender, hospitalization, admission to intensive care unit (ICU), death, tumor diagnosis, prostate cancer diagnosis, and androgen-deprivation therapy (ADT).
Results There were 9280 SARS-CoV-2 positive patients in the Veneto on April 1, 2020. Overall, males developed more severe complications, were more frequently hospitalized, and had a worse clinical outcome than females. Considering only the Veneto male population (2.4 Million men), 0.2% and 0.3% of non-cancer and cancer patients, respectively, tested positive for SARS-CoV-2.
Comparing the total number of SARS-CoV-2 positive cases, prostate cancer patients receiving ADT had a significantly lower risk of SARS-CoV-2 infection compared to patients who did not receive ADT (OR 4.05; 95% CI 1.55-10.59). A greater difference was found comparing prostate cancer patients receiving ADT to patients with any other type of cancer (OR 5.17; 95% CI 2.02-13.40).
Conclusion Our data suggest that cancer patients have an increased risk of SARS-CoV-2 infections than non-cancer patients. However, prostate cancer patients receiving ADT appear to be partially protected from SARS-CoV-2 infections.
Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532). Annals of Oncology 2020. http://www.sciencedirect.com/science/article/pii/S0923753420397970
Thanks for this post, Doc. After doing a fair but of research on D3 three the past 3 months, I've kicked my intake of D3 up to 40, 000 IU, will have it tested again in 3 months, after initially showing, like so many others, a deficiency. If anyone wants an eye opener as to everything D3 is involved in, do your due diligence. For those who want actual studies, just type in "vitamin D3" on PubMed and watch what comes up. And BTW, Vit. D3 isn't actually a vitamin, it's a hormone.
Thanks for this, Doc. After 3 months of my own research on D3, I started taking 40,000 iu of D3 a month ago, and having bloods done in 3 months after showing an initial deficiency, as a large section of the population shows also. Do your due diligence and research it to find out all the functions of this hormone (it's not a vitamin actually).
And for those wanting the hard research, check out PubMed and type in "vitamin D3."
Jankauskas
Member
Can nicotine help protect against covid 19?
Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19 - Article (Preprint v3) | Qeios
And there's other articles.
I found this very interesting. Back at the end of January and early February, my girl got sick with the "flu" twice, pretty much back to back. She felt fatigue, body aches, a fever that approached 102, dry cough, and at the end of the second time, lost her voice. We both think it's possible she had covid. The second time she went to see a doctor who was surprised and concerned about the double flu. I took care her, we live together, but neither time did I get sick, at all.
I used to dip tobacco ocasionally, but found a product called Zyn. Its nicotine salt, in a pouch with flavor and sweeter. I use them almost daily. Yes, I'm a nicotine addict. But I can stop anytime I want to, I swear
. They come 3 and 6mg per pouch and and pack more of a buzz than dipping. So I wondered.
Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19 - Article (Preprint v3) | Qeios
And there's other articles.
I found this very interesting. Back at the end of January and early February, my girl got sick with the "flu" twice, pretty much back to back. She felt fatigue, body aches, a fever that approached 102, dry cough, and at the end of the second time, lost her voice. We both think it's possible she had covid. The second time she went to see a doctor who was surprised and concerned about the double flu. I took care her, we live together, but neither time did I get sick, at all.
I used to dip tobacco ocasionally, but found a product called Zyn. Its nicotine salt, in a pouch with flavor and sweeter. I use them almost daily. Yes, I'm a nicotine addict. But I can stop anytime I want to, I swear
. They come 3 and 6mg per pouch and and pack more of a buzz than dipping. So I wondered.
Last edited:
.
master.on
New Member
Funny how leftists politics makes doctors wish for potential cures to fail.
Talk about becoming Dr. Mengele like.
Hydroxychloroquine "trials" were actually designed to FAIL because:
1. Zinc wasn't added
2. HCQ patients were the sickest, and often HCQ was given just before patients were sent to ICU. Of course HCQ (or any med) was going to fail when given so late to so ill patients.
If you spent less time whining about Trump (to try to justify your wrongful life decisions, like prescribing steroids for no reason), and you spent some time reading medical or scientific articles like a real doctor would, you'd become a better person.
This is what a real doctor should behave like:
[OA] What does androgenetic alopecia have to do with COVID-19?
Dear Editor
In late 2019, a novel coronavirus, subsequently named SARS‐CoV‐2 (COVID‐19), was first reported in Hubei province in China. Since it was first reported, a worldwide pandemic has ensued affecting more than 450 000 individuals as of March 2020. In the midst of the pandemic, epidemiological reports unveiled a disproportionate low rate of severe cases among adult females compared to adult males, 42% and 58%, respectively.1 Similarly, the rate of severe cases among pre‐pubescent children was exceptionally low at 0.6%.1 An explanation for the skewed prevalence of severe COVID‐19 infection in adult males has yet to be elucidated.
…
Goren A, McCoy J, Wambier CG, et al. What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy [published online ahead of print, 2020 Apr 1]. Dermatol Ther. 2020;e13365. doi:10.1111/dth.13365 Error - Cookies Turned Off
Dear Editor
In late 2019, a novel coronavirus, subsequently named SARS‐CoV‐2 (COVID‐19), was first reported in Hubei province in China. Since it was first reported, a worldwide pandemic has ensued affecting more than 450 000 individuals as of March 2020. In the midst of the pandemic, epidemiological reports unveiled a disproportionate low rate of severe cases among adult females compared to adult males, 42% and 58%, respectively.1 Similarly, the rate of severe cases among pre‐pubescent children was exceptionally low at 0.6%.1 An explanation for the skewed prevalence of severe COVID‐19 infection in adult males has yet to be elucidated.
…
Goren A, McCoy J, Wambier CG, et al. What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy [published online ahead of print, 2020 Apr 1]. Dermatol Ther. 2020;e13365. doi:10.1111/dth.13365 Error - Cookies Turned Off
Similar threads
Sponsors
Latest posts
-
Qingdao Sigma Chemical Co., Ltd (International, US, EU, Canada and Australia domestic
- Latest: addicted2peptidez
-
Minimum amount of bac water to add to hgh vial
- Latest: LeeroyMatinta
-
-
-